GSS genetic signatures limited

News: GSS Genetic Signatures Says Influenza B Detection Expected To Impact On Quarter Sales

  1. 193,698 Posts.
    lightbulb Created with Sketch. 2825

    Aug 25 (Reuters) - Genetic Signatures Ltd (GSS) :

    • INFLUENZA B DETECTION EXPECTED TO IMPACT ON QUARTER SALES
    • A UNDERTAKEN AN INVESTIGATION
    • WELL-ADVANCED IN RESOLVING THE ISSUE, WHICH IS SPECIFIC TO INFLUENZA B VIRUS
    • FOUND SEASON'S INFLUENZA B VIRUS IS NOT BEING CONSISTENTLY DETECTED IN A SMALL PROPORTION OF LOW VIRAL CONCENTRATION SAMPLES
    • AT THIS TIME, WE EXPECT FORECAST REVENUE TO BE ABOUT A$2 MILLION FOR Q1 FY2023
    • DETECTION OF INFLUENZA A VIRUS IS UNAFFECTED.
    • IN INTERIM, SALE OF GENETIC SIGNATURES EASYSCREEN™ RESPIRATORY PATHOGEN DETECTION KIT HAS BEEN IMPACTED DURING THIS CURRENT QUARTER
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
36.5¢
Change
-0.010(2.67%)
Mkt cap ! $82.90M
Open High Low Value Volume
36.5¢ 36.5¢ 36.5¢ $160 438

Buyers (Bids)

No. Vol. Price($)
3 19601 36.5¢
 

Sellers (Offers)

Price($) Vol. No.
37.5¢ 32411 1
View Market Depth
Last trade - 13.38pm 04/07/2025 (20 minute delay) ?
GSS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.